NorthWest Biotherapeutics Inc (NWBO)

[pgsd]

$NWBO

Merck continues its loosing streak with Keytruda combos.

Merck states:

"Merck is not investing as much in other co-formulations of Keytruda with other immuno-oncology targets and that TIGIT seems to be the most promising."

Thats funny! 🤔 -->https://t.co/0bl0hKojlE

— 🇩🇰 The Danish Dude 🇩🇰 (@FlemmingBruce) March 17, 2023

Because Keytruda is currently in a combo trial at UCLA, the prestigious SPORE trial, where Keytruda is donated for FREE - unheard of - by Merck.

Merck has chosen NOT to PR the interim results that Keytruda in combo with DCVax-L has more than 50% efficacy against brain cancer.

— 🇩🇰 The Danish Dude 🇩🇰 (@FlemmingBruce) March 17, 2023

pic.twitter.com/gBJ0xcadpw

— 🇩🇰 The Danish Dude 🇩🇰 (@FlemmingBruce) March 17, 2023